China Kanghui Holdings, which is a leading China-based manufacturer and marketer of orthopedic implants, announced terms for its IPO on Wednesday. The Changzhou-based company plans to raise $68 million by offering 6.7 million ADSs at a price range of $9.25-$11.25. At the mid-point of the proposed range, China Kanghui will command a market value of $223 million. China Kanghui, which was founded in 1997 and booked $29 million in sales for the 12 months ended March 31, plans to list on the NYSE under the symbol KH. Morgan Stanley and Piper Jaffray are the lead underwriters on the deal, which is expected to price during the week of August 9.
